Unknown

Dataset Information

0

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.


ABSTRACT: BACKGROUND:To analyze the effects of BRCA1/2 mutations on chemotherapy response scores (CRS) and survival in a cohort of patients with advanced-stage ovarian cancer who were treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). METHODS:We retrospectively reviewed the medical records of 169 high-grade serous ovarian cancer patients who underwent a germline BRCA1/2 test and received three cycles of NAC at the Yonsei Cancer Center from 2006 to 2018. Chemotherapy response scores were compared in patients with and without BRCA1/2 mutations. The effects of BRCA1/2 mutations and CRS on survival were evaluated. RESULTS:BRCA1/2 mutations were detected in 47 (28.1%) of the 169 patients. Overall, 16 (34.0%) patients with BRCA1/2 mutations had a CRS 3 to chemotherapy compared to scores of 43 in patients (35.2%) without a mutation. Response scores of 3 in patients with BRCA1/2 mutations were not significantly associated with either improved progression-free survival (PFS) (P?=?0.949) or overall survival (OS) (P?=?0.168). However, CRS 3 in patients without BRCA mutations was significantly associated with both improved PFS (P?=?0.030) and OS (P?=?0.039). In patients with CRS1/2, carriers of BRCA1/2 mutations had better PFS (P?=?0.0344) and OS (P?=?0.043) than wild-type BRCA genotype patients. CONCLUSION:In ovarian cancer patients treated with NAC, CRS did not predict survival for BRCA 1/2 mutation carriers but did for BRCA wild-type patients.

SUBMITTER: Lee YJ 

PROVIDER: S-EPMC7057666 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.

Lee Yong Jae YJ   Kim Hyun-Soo HS   Rim John Hoon JH   Lee Jung-Yun JY   Nam Eun Ji EJ   Kim Sang Wun SW   Kim Sunghoon S   Kim Young Tae YT  

BMC cancer 20200304 1


<h4>Background</h4>To analyze the effects of BRCA1/2 mutations on chemotherapy response scores (CRS) and survival in a cohort of patients with advanced-stage ovarian cancer who were treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS).<h4>Methods</h4>We retrospectively reviewed the medical records of 169 high-grade serous ovarian cancer patients who underwent a germline BRCA1/2 test and received three cycles of NAC at the Yonsei Cancer Center from 2006 to 2018  ...[more]

Similar Datasets

| S-EPMC7249312 | biostudies-literature
| S-EPMC9905268 | biostudies-literature
| S-EPMC8287765 | biostudies-literature
| S-EPMC8918010 | biostudies-literature
| S-EPMC10079604 | biostudies-literature
| S-EPMC3413277 | biostudies-literature
| S-EPMC5584794 | biostudies-literature
| S-EPMC7915369 | biostudies-literature
| S-EPMC7693629 | biostudies-literature
| S-EPMC5994186 | biostudies-literature